

Zeitschrift: Bulletin der Schweizerischen Akademie der Medizinischen Wissenschaften = Bulletin de l'Académie suisse des sciences médicales = Bollettino dell' Accademia svizzera delle scienze mediche

Herausgeber: Schweizerische Akademie der Medizinischen Wissenschaften

Band: 13 (1957)

Heft: 1-4: Symposium über Arteriosklerose = Symposium sur l'artériosclérose
= Symposium on arteriosclerosis

Titelseiten

Nutzungsbedingungen

Die ETH-Bibliothek ist die Anbieterin der digitalisierten Zeitschriften. Sie besitzt keine Urheberrechte an den Zeitschriften und ist nicht verantwortlich für deren Inhalte. Die Rechte liegen in der Regel bei den Herausgebern beziehungsweise den externen Rechteinhabern. Siehe Rechtliche Hinweise.

Conditions d'utilisation

L'ETH Library est le fournisseur des revues numérisées. Elle ne détient aucun droit d'auteur sur les revues et n'est pas responsable de leur contenu. En règle générale, les droits sont détenus par les éditeurs ou les détenteurs de droits externes. Voir Informations légales.

Terms of use

The ETH Library is the provider of the digitised journals. It does not own any copyrights to the journals and is not responsible for their content. The rights usually lie with the publishers or the external rights holders. See Legal notice.

Download PDF: 20.05.2025

ETH-Bibliothek Zürich, E-Periodica, <https://www.e-periodica.ch>

3. Klinik und Therapie – Clinique et thérapeutique – Clinic and therapy

D.C. 616.13-002.2-08

Wayne State University, Detroit 2, Michigan
Providence Hospital, Detroit, Michigan

Studies in human and induced Atherosclerosis employing Ethylenediaminetetraacetic acid¹

By **Albert J. Boyle, J. J. Jasper, Herbert McCormick,
Mary Kosai, Daisy McCann, and Jesse Goodwin
Norman E. Clarke, and Robert E. Mosher**

Before discussing the use of salts of ethylenediaminetetraacetic acid (EDTA) in the treatment of coronary artery disease I would like to point out a few of the experimental findings in rabbits with induced atherosclerosis made by our group at Wayne State University, Detroit, Michigan. It also would appear pertinent to discuss at some length the philosophy which led to the use of EDTA in atherosclerosis and suggests its further use in several metabolic disorders.

In our early experimental work (1) it was shown that rabbits (Group B) placed on a high cholesterol diet and injected subcutaneously with 500 mg of sodium EDTA every other day developed serum cholesterol levels that were elevated above that of similarly fed control animals designated Group A (Fig. 1). On sacrifice, all test animals, numbering eleven in each group, presented aortic atherosclerotic plaques. One impressive finding was the marked decrease of liver fat and cholesterol in the injected group (Fig. 2) as revealed by inspection and chemical analysis. Serum electrolyte studies in this series of animals showed a depression in serum calcium levels (Fig. 3) though considerably greater in the injected Group B at the midpoint of the experiment which lasted 111 days². Thereafter, however, Group B serum calcium rose to meet the level noted in Group A. Serum magnesium fell initially in both groups and ultimately returned

¹ Financed by Grant-in-Aid from the Michigan Heart Association and Ciba Pharmaceutical Products, Inc.

² From day 48 to 72 no injections of EDTA were given to Group B. During part of this period CaEDTA was fed.